Pre-made Vepsitamab benchmark antibody ( Whole mAb, anti-MUC17;CD3E therapeutic antibody, Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-708

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-708 Category Tags ,

Product Details

Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Vepsitamab

Target

MUC17,CD3E

Format

Bispecific scFv-scFv-scFc

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

na;na

VD LC

Lambda,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2021

Companies

Amgen

Conditions Approved

NA

Conditions Active

GE Junction Cancer,Gastric Adenocarcinoma

Conditions Discontinued

NA

Development Tech

BiTE Technology

Previous Name

NA

Gm Offical Target Name

MUC17,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide